Featured in this edition of iSpeak Reading Roundup, are the top blog posts from October 2019. See leading facilities, break-through therapies, innovative technologies, and more for what the pharmaceutical industry was reading in October.
Learn more about how modular and podular construction designs can shape facilities of biopharmaceutical manufacturing. These facility designs can have the ability to address the severity of natural disasters and the impact on vulnerable populations globally.
This year’s category winner proved excellence in the incorporation of novel technologies, improved efficiencies, and success in eliminating challenges. Read more about Pfizer’s first modular biological production facility!
See the updates and new changes to EU Clinical Trial Regulation, including a single approach for the application and maintenance of the CT authorisation and this applies to trials whether they are multi-member state or mono-state.
Review current challenges validation experts are facing when implementing programs for advanced manufacturing. Key ideas addressed are continuous validation techniques and multi-step production challenges.
Discover how AveXis overcame challenges in execution and delivery of novel treatments for patients affected by rare and life-threatening neurological genetic diseases. The company received an Honorable Mention Award for this year’s competition.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...